Trial Profile
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Myocardial infarction; Peripheral arterial disorders; Peripheral ischaemia; Stroke; Thrombosis; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VOYAGER PAD
- Sponsors Bayer; Bayer HealthCare; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- 14 Nov 2023 According to Janssen media release, results from this trial were presented at the American Heart Association's (AHA) 2023 Scientific Sessions.
- 14 Nov 2023 Results assessing the role of XARELTO in treating both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD) presented in the Janssen Media Release.
- 13 Nov 2023 Results analyzing impact of low dose Rivaroxaban Plus Aspirin on myocardial infarction in patients with peripheral artery disease with and without concomitant coronary artery disease, presented at the American Heart Association Scientific Sessions 2023